R
RevBio
LaunchPad Medical is developing the first bone adhesive to repair bone fractures and stabilize metal implants
About RevBio
RevBio, headquartered in Lowell, Massachusetts, is a pioneering company in the field of bioengineered medical adhesives. The company has developed TETRANITE, a patented synthetic bone adhesive inspired by the sandcastle worm, which is designed to resorb and be replaced by natural bone over time. This innovative product addresses the needs of clinicians by providing a solution that does not require ancillary fixation devices such as screws or tacks.
RevBio operates primarily in the healthcare and dental markets, serving clinicians and medical professionals who require advanced solutions for bone repair and stabilization. The company's business model revolves around the development, patenting, and commercialization of its bioadhesive technology. Revenue is generated through the sale of its products, as well as through grants and partnerships.
RevBio has a strong foundation in research and development, supported by an extensive team of scientists, engineers, and clinicians. The company has received multiple patents and has won over 10 grants, underscoring its innovative capabilities. Currently, RevBio is conducting its first human clinical trial to further validate the efficacy of its biomimetic bone adhesive.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2014
- Headquarters
- Lowell, United States
- Employees
- 37
- Open positions
- 1
- Dealroom signal
- 78.5/100
- Industry
- Health
- Sub-industry
- BioTechnology, Medical Devices
- Sector
- Biotech & Life Sciences, Biotechnology, Biomaterials, Non-Invasive medical devices and treatments, Biotech and Pharma, Hard Tech, DT and LS, science-based
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| GRANT✓Other financing | Oct 2025 | $2.2M | — | National Institute on Aging | ↗ |
| GRANTOther financing | Sep 2024 | $2.4M | — | National Institute of Neurological Disorders and Stroke | — |
Growth signals
Latest recorded traffic for RevBio is 2.7K monthly website visits, up 3.8% over the last three months. RevBio's team grew 5.7% over the past year.
Open positions
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed5 investors entered at this stage
Boston Harbor Angels
MassChallenge
National Institute on Aging
Small Business Innovation Research
National Institute of Neurological Disorders and Stroke
Series A4 investors entered at this stage
- TGThe Jha Group
Delta Dental of Washington
Beacon Angels- APAriel Southeast Angel Partners
Other known investors3 additional known investors
MedTech Innovator
Pacific Dental Services
Greyhill Capital Partners
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about RevBio on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See RevBio’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.